Only Sjögren's syndrome Phase 2 trial to meet the primary endpoint in both patient population types Patients with moderate-to-severe systemic disease activity (ESSDAI score =5) treated
Only Sjögren’s syndrome Phase 2 trial to meet the primary endpoint in both patient population types Patients with moderate-to-severe systemic disease activity treated with. | May 31, 2023
The Texas Tech University Health Sciences Center (TTUHSC) family is deeply saddened to announce the untimely death today (May 26) of TTUHSC Executive Vice President and School of Medicine Dean Dr. Steven L. Berk.